Stock Research for ADRU


Featured Broker: Ally Invest

Get the due diligence for another stock.


ADRU Stock Chart & Research Data

The ADRU chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRU chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ADRU Due diligence Resources & Stock Charts

The ADRU stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADRU Detailed Price Forecast - CNN Money CNN View ADRU Detailed Summary - Google Finance
Yahoo View ADRU Detailed Summary - Yahoo! Finance Zacks View ADRU Stock Research & Analysis -

Stock Analysis

TradeIdeas View ADRU Trends & Analysis - Trade-Ideas Barrons View ADRU Major Holders - Barrons
NASDAQ View ADRU Call Transcripts - NASDAQ Seeking View ADRU Breaking News & Analysis - Seeking Alpha
Spotlight View ADRU Annual Report - OTC Report View ADRU OTC Short Report -
TradeKing View ADRU Fundamentals - TradeKing Charts View ADRU SEC Filings - Bar Chart
WSJ View Historical Prices for ADRU - The WSJ Morningstar View Performance/Total Return for ADRU - Morningstar
MarketWatch View the Analyst Estimates for ADRU - MarketWatch CNBC View the Earnings History for ADRU - CNBC
StockMarketWatch View the ADRU Earnings - StockMarketWatch MacroAxis View ADRU Buy or Sell Recommendations - MacroAxis
Bullish View the ADRU Bullish Patterns - American Bulls Short Pains View ADRU Short Pain Metrics -

Social Media Mentions

StockTwits View ADRU Stock Mentions - StockTwits PennyStocks View ADRU Stock Mentions - PennyStockTweets
Twitter View ADRU Stock Mentions - Twitter Invest Hub View ADRU Investment Forum News - Investor Hub
Yahoo View ADRU Stock Mentions - Yahoo! Message Board Seeking Alpha View ADRU Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ADRU - Insider Cow View Insider Transactions for ADRU - Insider Cow
CNBC View ADRU Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADRU - OTC Markets
Yahoo View Insider Transactions for ADRU - Yahoo! Finance NASDAQ View Institutional Holdings for ADRU - NASDAQ

Stock Charts

FinViz View ADRU Stock Insight & Charts - StockCharts View ADRU Investment Charts -
BarChart View ADRU Stock Overview & Charts - BarChart Trading View View ADRU User Generated Charts - Trading View

Latest Financial News for ADRU

Recommendations for GlaxoSmithKline on October 29
Posted on Monday October 29, 2018

Wall Street analysts are estimating that GlaxoSmithKline will report revenues of ~8.02 billion pounds for the third quarter of 2018. GlaxoSmithKline stock has increased ~8.5% over the last 12 months and ~10.8% year-to-date. Analyst recommendations show a 12-month target price of $44.31 per share compared to its last price of $39.32 on October 26.

What Analysts Recommend for Novartis after Q3 Earnings
Posted on Wednesday October 24, 2018

Wall Street analysts estimate that Novartis will report revenues of $13.4 billion during the fourth quarter of 2018, a 4.0% increase in year-over-year revenues as compared to $12.9 billion during the fourth quarter of 2017. The earnings-per-share is estimated at $1.29 during the fourth quarter of 2018. Analysts estimate the net income margin to increase to 22.1% during the fourth quarter of 2018 as compared to 21.8% during the fourth quarter of 2017.

How Novartis’s Innovative Medicines Business Performed in Q3
Posted on Monday October 22, 2018

Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.

A Closer Look at Novartis’s Innovative Medicines Segment
Posted on Wednesday October 10, 2018

Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.